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Abstract
Heparin-induced thrombocytopenia (HIT) is the most important and most frequent drug-induced,
immune-mediated type of thrombocytopenia. It is associated with significant morbidity and
mortality if unrecognized. In this review, we briefly discuss the main features of heparin-induced
thrombocytopenia, particularly analyzing the most recent advances in the pathophysiology,
diagnosis and treatment of this syndrome.
Introduction
Heparin is a drug widely used for thromboprophylaxis or
treatment in many clinical situations, including cardio-
vascular surgery and invasive procedures, acute coronary
syndromes, venous thromboembolism, atrial fibrillation,
peripheral occlusive disease, dialysis and during extracor-
poreal circulation [1,2]. However, it can cause serious
adverse effects, including heparin-induced thrombocyto-
penia (HIT) which is a common, serious and potentially
life-threatening condition [3-6]. Unfortunately, because
thrombocytopenia is common in hospitalized patients
and can be caused by a variety of factors [7], HIT often
remains unrecognized.
Heparin-induced thrombocytopenia is defined as a
decrease in platelet count during or shortly following
exposure to heparin [8]. Two different types of HIT are rec-
ognized. The first, HIT type I (also called heparin-associ-
ated thrombocytopenia in the past), is a benign form not
associated with an increased risk of thrombosis. The
mechanism of HIT type I is still unknown but it is likely to
be non-immune, probably related to its platelet pro-
aggregating effect. This form of HIT affects up to 10% of
patients under treatment with heparin and is character-
ized by a mild and transient asymptomatic thrombocyto-
penia (rarely less than 100,000 platelets/µL) that develops
early (usually within the first two days of starting heparin)
and disappears equally quickly once the heparin is with-
drawn. The second form of HIT, HIT type II, is immune-
mediated and associated with a risk of thrombosis. It has
recently been proposed that the term "HIT type I" be
changed to "non-immune heparin associated thrombocy-
topenia" and that the term "HIT type II" be changed to
"HIT" to avoid confusion between the two syndromes [9].
In this review we briefly analyze the main characteristics
of the clinically relevant, immune-mediated, second type
of HIT, focusing particularly on the epidemiology, patho-
physiology, clinical manifestations and treatment of this
syndrome. For simplicity and also in accordance with the
new recommendations, in the following the term HIT
refers to HIT type II.
Incidence
Heparin-induced thrombocytopenia is the most impor-
tant of the immune-mediated, drug-induced
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thrombocytopenias. Recent data show that up to 8% of
heparinized patients will develop the antibody associated
with HIT [10] and that approximately 1–5% of patients
on heparin will progress to develop HIT with thrombocy-
topenia [11,12], suffering from venous and/or arterial
thrombosis in at least one-third of cases [13,14]. In a
recent analysis of 598 consecutive hospitalized medical
patients treated with subcutaneous unfractionated
heparin, Girolami and colleagues diagnosed five cases of
HIT (0.8%) [15]. In general, the antibodies occur more
frequently in patients undergoing cardiovascular surgery
than those undergoing orthopedic surgery, and in post-
surgical patients than in medical patients. HIT antibodies
are also more frequent in patients receiving unfraction-
ated heparin (UFH) than in those treated with low molec-
ular weight heparin (LMWH) [16,17], although it must be
highlighted that antibodies developing in patients receiv-
ing UFH frequently cross-react with LMWH [13]. In a
study conducted on 665 patients undergoing elective hip
arthroplasty who had been randomized to receive either
UFH or LMWH for thromboprophylaxis, Warkenitin and
colleagues reported that HIT occurred in 9 of 332 patients
who received UFH and in none of 333 patients who
received LMWH (2.7% versus 0%, P = 0.0018) [10]. In
addition, development of heparin-dependent antibodies
and thrombotic events associated with thrombocytopenia
were more common in patients treated with UFH than in
those treated with LMWH.
Pathophysiology
The mechanism underlying heparin-induced thrombocy-
topenia is an immune response [18,19]. The principal
antigen is a complex of heparin and platelet factor 4
(PF4). Platelet factor 4 is a small positively charged mole-
cule of uncertain biological function normally found in α-
granules of platelets. When platelets are activated, PF4 is
released into the circulation and some of it binds to the
platelet surface. Because of opposite charges, heparin and
other glycosaminoglycans bind to the PF4 molecules,
exposing neoepitopes that act as immunogens leading to
antibody production. In fact, patients who develop HIT
produce an IgG antibody against the heparin-PF4 com-
plex, which binds to the complex on platelet surface
through the Fab region [20]. The Fc portion of the HIT
antibody can then bind to the platelet Fc receptor and this
interaction triggers activation and aggregation of the
platelets. Activated platelets release PF4, thus perpetuating
the cycle of heparin-induced platelet activation. In addi-
tion, the platelet activation leads to the production of pro-
thrombotic platelet microparticles which promote
coagulation. Finally, as a result of the presence of heparin-
like molecules (heparan sulfate) on the surface of
endothelial cells, the HIT antibody-PF4-heparan sulfate
complexes formed on the endothelial surface may induce
tissue factor expression with further activation of the coag-
ulation cascade and thrombin generation [21,22]. Throm-
bocytopenia in HIT is largely due to the clearance of
activated platelets and antibody-coated platelets by the
reticulo-endothelial system [1]. Figure 1 illustrates the
pathophysiology of HIT.
Clinical features and diagnosis
The onset of heparin-induced thrombocytopenia may be
rapid or delayed. The platelet count in patients with pre-
existing heparin-PF4 antibodies from a previous exposure
and sensitization to heparin may decrease within the first
3 days or even hours after re-exposure to heparin (rapid-
onset HIT) [23]. However, in patients receiving heparin
for the first time, the onset of thrombocytopenia usually
occurs 5 to 10 days after the administration of the
heparin. Conversely, in delayed-onset HIT, the thrombo-
cytopenia occurs 5 or more days after heparin withdrawal
[24].
Pathophysiology of heparin induced thrombocytopenia Figure 1
Pathophysiology of heparin induced thrombocytopenia.
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The thrombocytopenia in HIT is usually moderate in
severity, with a median platelet count being between 50
and 80 × 109/L, although the nadir platelet count can
remain at a level considered normal (i.e. > 150 × 109/L)
but having dropped by 50% or more with respect to the
pre-heparin value. The platelet count starts to rise 2 to 3
days after discontinuing heparin and usually returns to
normal within 4 to 10 days. The antibody disappears
within 2 to 3 months after cessation of heparin therapy
[11]. Although HIT does not invariably recur during sub-
sequent re-exposure to heparin, future use of heparin is
contraindicated [25]. Despite thrombocytopenia, bleed-
ing is rare [2]. Contrariwise, HIT is strongly associated
with thrombosis, which frequently leads to the recogni-
tion of HIT [26]. Thrombosis in HIT is associated with a
mortality of approximately 20–30%, with an equal per-
centage of patients becoming permanently disabled by
amputation, stroke or other causes [27]. Thromboem-
bolic complications can be venous, arterial, or both and
include deep venous thrombosis, pulmonary embolism,
myocardial infarction, thrombotic stroke and occlusion of
limb arteries [28]. However, the type and site of thrombo-
sis depends on the patient's clinical profile. For example,
deep vein thrombosis and pulmonary embolism occur
very frequently in postoperative patients who are already
prone to developing venous thromboembolism [10]. In
fact, Warkentin and colleagues reported that the incidence
of deep vein thrombosis in orthopedic patients who
received heparin for thromboprophylaxis was 17.8%, but
that this incidence increased dramatically to 88.9%
among patients who developed HIT [10]. Similarly,
patients with central venous catheters and HIT develop
upper limb venous thrombosis more frequently than
those without HIT [1]. In some cases thrombosis of the
cerebral venous sinuses can occur, giving rise to a clinical
picture of severe headache and progressive neurological
deficits [29]. In contrast, arterial thrombosis occurs more
frequently than venous thrombosis in HIT patients receiv-
ing heparin for cardiovascular diseases [30]. Furthermore,
areas of necrosis developing at the site of heparin injec-
tions can be a manifestation of HIT, and are not necessar-
ily associated with thrombocytopenia [31]. Platelet
activation and thrombosis due to heparin-dependent,
platelet-activating IgG have been shown to be the under-
lying pathogenic mechanisms of this complication [31].
In some cases, thrombosis may be generalized leading to
a syndrome resembling disseminated intravascular coagu-
lation [32].
Finally, in some patients with HIT resistance to heparin
may occur, meaning that an increasing dose of heparin
dose is required to maintain the activated partial throm-
boplastin time (aPTT) within the therapeutic range [13].
The diagnosis of HIT remains a clinical one, supported by
confirmatory laboratory testing [5,6]. The criteria include:
a) thrombocytopenia (i.e., a drop of the platelet count to
below 100 × 109/L or a drop of > 50% from the patient's
baseline platelet count); b) the exclusion of other causes
of thrombocytopenia; c) the resolution of thrombocyto-
penia after cessation of heparin [1]. As regards the labora-
tory tests, HIT-antibodies can be demonstrated in vitro by
functional tests and immunoassays [4,8]. Functional tests,
which measure platelet activity in the presence of the
patient's serum and heparin, include heparin-induced
platelet aggregation (HIPA) and the serotonin release
assay (SRA). Although the HIPA test is easier to perform
and thus more commonly used, the SRA is more sensitive,
albeit more complex, technically demanding and not
readily available in most centers, and is therefore consid-
ered the "gold standard" [1]. The immunoassays utilize
immunoenzymatic tests (enzyme-linked immunesorbent
assay, ELISA) to detect the HIT antibody that binds to the
PF4/heparin complex. Immunoassays are technically eas-
ier to perform than the functional assays and are also
more sensitive [1]. On the other hand, comparative and
prospective studies have demonstrated that functional
tests are more specific than enzyme immunoassays and
thus, being better at detecting the clinically significant HIT
antibodies, are more helpful in the diagnosis of HIT [3].
Treatment
When HIT is suspected clinically, immediate cessation of
all formulations of heparin is mandatory, but this will nei-
ther stop continuing thrombin generation nor avoid sub-
sequent thrombotic events, which occur in as many as 40–
50% of the patients over the next several days or weeks
[33]. Interestingly, in a retrospective analysis of 113
patients with HIT, Wallis and colleagues [34] found that
early heparin cessation (0.7 ± 0.6 days) was no more effec-
tive in reducing morbidity and mortality than was late
heparin cessation (5 ± 3 days), thus indicating that
heparin cessation alone is not sufficient treatment for HIT.
In fact, the appropriate treatment for HIT requires imme-
diate removal of the trigger (heparin cessation) as well as
control of the thrombin storm of HIT (by providing
appropriate alternative anticoagulation). Currently, three
non-heparin anticoagulants that do not cross-react with
HIT antibodies, danaparoid, lepirudin and argatroban,
are available for alternative anticoagulation in HIT [35-
41]. These drugs are immediately active and either inhibit
thrombin directly or inhibit thrombin generation. As
reported above, LMWH cannot be used in patients with
HIT because of the strong cross-reactivity of the HIT anti-
body with the LMW heparin/PF4 complex. The duration
of treatment for patients with HIT is not well defined.
However, anticoagulation treatment is required for at
least 2 to 3 months to prevent recurrence of thrombosis.
Oral anticoagulation with warfarin should be initiatedThrombosis Journal 2005, 3:14 http://www.thrombosisjournal.com/content/3/1/14
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until substantial platelet count recovery has occurred and
while the patient is receiving danaparoid or a thrombin-
specific inhibitor (an overlap of at least 5 days is recom-
mended) [33]. In fact, it has recently become known that
HIT patients who are switched to warfarin alone after the
discontinuation of heparin may paradoxically have wors-
ening thrombosis and develop venous limb gangrene and
skin necrosis [42]. The mechanism appears to be a warfa-
rin-induced marked decrease in protein C before pro-
thrombin levels are adequately suppressed [2].
Danaparoid has been successfully used as a replacement
for heparin in patients with HIT [43]. This anticoagulant
is composed of a mixture of three glycosaminoglycans
(heparin sulfate, dermatan sulfate and chondroitin sul-
fate) and, via antithrombin, inhibits anti-FXa activity. In a
prospective randomized study conducted by Chong and
colleagues [41], danaparoid was shown to be more effec-
tive than dextran 70 in the treatment of HIT-associated
venous and arterial thrombosis. In a compassionate use
program, more than 460 patients with HIT-associated
thrombosis were treated with danaparoid with a success
rate of over 90% [44]. For treatment of HIT, danaparoid is
given as an intravenous bolus dose of 2500 U followed by
400 U/hour for 4 hours, then 300 U/hour for 4 hours and
subsequently 200 U/hour until anticoagulation is no
longer required, adjusting the dose to maintain plasma
anti-Xa levels within 0.5–0.8 U/mL. Alternatively, dana-
paroid can be administered subcutaneously using a bolus
of 1250 U followed by 2000 U twice a day [1].
Recombinant hirudin (lepirudin), an anticoagulant pro-
tein originally produced by the medicinal leech, inhibits
thrombin directly [1]. In a meta-analysis of three prospec-
tive multicenter trials including 91 patients with labora-
tory-confirmed acute HIT treated with lepirudin,
Lubenow and colleagues [45] found that the incidence of
the combined end-point of death, new thromboembolic
complications and limb amputation was significantly
lower in the lepirudin-treated patients than in a contem-
poraneous control group not treated with lepirudin. Cur-
rently recommended doses are 0.4 mg/kg as a bolus
followed by 0.15 mg/kg/hour adjusting the dose to
achieve an aPTT of 1.5 to 3 times the baseline value [33].
In a retrospective study of 175 lepirudin-treated HIT
patients and 126 danaparoid-treated HIT patients, Farner
and colleagues [46] found no significant difference in the
same combined end-points between the two groups.
Argatroban, an arginine-based synthetic anticoagulant, is
a direct inhibitor of thrombin that reversibly binds the
catalytic site of thrombin [13,47]. A multicenter, prospec-
tive study conducted on 304 HIT patients receiving arga-
troban found that the above mentioned combined end-
points were significantly reduced in argatroban-treated
patients compared to in historical controls [40]. The rec-
ommended initial dose is 2 µg/kg/minute given intrave-
nously and adjusted to achieve an aPTT 1.5 to 3 times the
baseline value. Since argatroban is cleared by the liver,
lepirudin, which is cleared through the kidneys, should be
preferred in patients with liver disease. Vice versa, arga-
troban would be a better initial choice in patients with
renal insufficiency. Thrombin-specific inhibitors also pro-
long the INR, but this effect is particularly pronounced
with argatroban [48]. Thus, during the transition from
argatroban to oral anticoagulation special precautions
must be taken [49,50].
Finally, there is recent evidence that a novel synthetic
heparin pentasaccharide, fondaparinux, which does not
cross-react with HIT antibodies [51], can be successfully
used for the treatment of patients with HIT [52,53]. How-
ever, additional controlled clinical studies are required to
further evaluate the safety and efficacy of this agent in
patients with HIT.
Conclusion
The analysis of the literature data reveals that heparin-
induced thrombocytopenia is not only a common but
also a serious complication of heparin therapy with a high
rate of morbidity and mortality. Its prompt clinical and
laboratory recognition is thus essential in order to stop
heparin use immediately and commence an alternative
anticoagulant. The low molecular weight heparinoid,
danaparoid, and the thrombin-specific inhibitors, lepiru-
din and argatroban, have been shown to be effective in
HIT patients.
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